Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MMRV vaccine
MMRV · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| MMRV | BIOLOGICAL | - |
| MMR (Priorix®) | BIOLOGICAL | - |
| Varicella (Varilrix®) | BIOLOGICAL | - |
Inclusion Criteria: * Written informed consent from the parents/guardians of the child before participating in the long-term follow-up. * Subjects must have received their complete vaccination course according to the group allocation (i.e. subjects must have received either two doses of MMRV combin...
MMRV is a vaccine used for rubella, as well as varicella, mumps, and measles. It is being developed by GSK plc for the prevention of these infectious diseases. The vaccine is currently in Phase 3 clinical development.
MMRV is a vaccine that targets the viruses that cause measles, mumps, rubella, and varicella. It is designed to provide immunity against these four infectious diseases. The vaccine is being developed by GSK plc.
MMRV is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 3 clinical development for the prevention of rubella, varicella, mumps, and measles.
MMRV is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The vaccine is being studied for the prevention of rubella, varicella, mumps, and measles.
MMRV has one completed Phase 3 clinical trial, NCT00406211, titled 'Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine'. The trial enrolled 398 participants in Austria and Germany and was a long-term follow-up study.
Yes, MMRV is the same as the MMRV vaccine. The drug is also known as the MMRV vaccine, which stands for Measles-Mumps-Rubella-Varicella combined vaccine. It is being developed by GSK plc for the prevention of these four infectious diseases.